<p>Crinetics Pharmaceuticals, Inc.（納斯達克代碼：CRNX - 免費報告）- HC Wainwright 的股票研究人員在 5 月 8 日星期五向投資者發佈的研究報告中下調了 Crinetics Pharmaceuticals 的 2030 財年收益預期。HC Wainwright 分析師 D. Tsao 現在預計該公司在這一年將每股盈利 2.65 美元，低於之前預測的 2.98 美元。市場普遍預計 Crinetics Pharmaceuticals 當前全年的每股收益為（4.95 美元）。</p>
<p>Crinetics Pharmaceuticals（納斯達克代碼：CRNX - 獲取免費報告）最近在 5 月 7 日星期四發佈了季度財報。該公司報告季度每股收益為（1.23 美元），低於市場普遍預期的（1.22 美元）0.01 美元。Crinetics Pharmaceuticals 的股本回報率為負 43.96%，淨利潤率為負 2,747.18%。該公司在本季度的收入為 1,073 萬美元，而市場普遍預期為 851 萬美元。去年同期，該公司每股收益為（1.04 美元）。該公司的季度收入同比增長 2873.4%。</p>
<p>其他幾位股票分析師也對該公司發佈了報告。Wall Street Zen 在週六的研究報告中將 Crinetics Pharmaceuticals 的評級從 “賣出” 下調至 “強烈賣出”。Lifesci Capital 在 2 月 13 日星期五的研究報告中將 Crinetics Pharmaceuticals 的評級上調至 “強烈買入”。Weiss Ratings 在 4 月 20 日星期一的報告中重新發布了對 Crinetics Pharmaceuticals 股票的 “賣出（d-）” 評級。高盛集團在 1 月 12 日星期一的研究報告中將 Crinetics Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。最後，Citizens Jmp 在週五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 97.00 美元下調至 95.00 美元，並對該股票設定了 “市場表現優於大盤” 的評級。一位研究分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Crinetics Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 76.50 美元。</p>
<p><strong>獲取我們對 CRNX 的最新分析</strong></p>
<h2>Crinetics Pharmaceuticals 股票表現</h2>
<p>CRNX 的股票在週一開盤價為 37.48 美元。該公司的 50 日移動平均價格為 38.41 美元，200 日移動平均價格為 43.89 美元。該公司的市值為 39.5 億美元，市盈率為 -7.31，貝塔值為 0.28。Crinetics Pharmaceuticals 的 52 周低點為 25.83 美元，52 周高點為 57.99 美元。</p>
<h2>內部人士下注</h2>
<p>在其他 Crinetics Pharmaceuticals 的新聞中，首席執行官 Richard Scott Struthers 於 3 月 16 日星期一出售了 21,981 股該股票。該股票以平均價格 37.37 美元出售，總價值為 821,429.97 美元。交易後，首席執行官持有該公司 404,778 股股票，價值約為 15,126,553.86 美元。這代表了他們持股比例的 5.15% 的減少。該交易在向 SEC 提交的文件中披露，相關信息可通過 SEC 網站訪問。此外，內部人士 Jeff E. Knight 於 4 月 8 日星期三出售了 85,163 股該公司的股票。該股票以平均價格 40.10 美元出售，總價值為 3,415,036.30 美元。交易後，內部人士持有該公司 105,289 股股票，價值約為 4,222,088.90 美元。這筆交易代表了他們持股比例的 44.72% 的減少。該銷售的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去三個月內出售了價值 5,569,475 美元的 142,380 股公司股票。內部人士持有該公司 3.80% 的股票。</p>
<h2>Crinetics Pharmaceuticals 的機構交易</h2>
<p>機構投資者和對沖基金最近修改了對該股票的持有。Dimensional Fund Advisors LP 在第一季度將其在 Crinetics Pharmaceuticals 的持倉增加了 55.2%。Dimensional Fund Advisors LP 現在擁有 852,258 股該公司的股票，價值 30,935,000 美元，在此期間又收購了 303,281 股。SEB Asset Management AB 在第一季度收購了 Crinetics Pharmaceuticals 的新頭寸，價值約為 7,769,000 美元。Principal Financial Group Inc. 在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 32.3%。Principal Financial Group Inc. 現在擁有 7,066 股該公司的股票，價值 257,000 美元，在上個季度又購買了 1,725 股。肯塔基州教師退休系統在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 4.0%。肯塔基州教師退休系統現在擁有 28,477 股該公司的股票，價值 1,034,000 美元，在上個季度又購買了 1,100 股。最後，Fifth Third Bancorp 在第一季度收購了 Crinetics Pharmaceuticals 的新股份，價值 126,000 美元。98.51% 的股票由機構投資者持有。</p>
<h2>關於 Crinetics Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於治療罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以解決由激素活動失調引起的疾病。Crinetics 的研究工作集中在針對生長抑素、抗利尿激素和其他 GPCR 介導的通路，旨在改善患者的便利性和依從性。</p>
<p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Crinetics Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關投資機會</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後獲得提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Crinetics Pharmaceuticals 並不在名單上。</p>
<p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRNX

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>HC Wainwright 已經修訂了 Crinetics Pharmaceuticals (NASDAQ:CRNX) 的 2030 財年盈利預期，將其從每股 2.98 美元下調至 2.65 美元。該公司當前全年的共識盈利預期為每股（4.95）美元。Crinetics 報告的季度虧損為每股（1.23）美元，略微低於預期。該公司經歷了 2873.4% 的顯著收入增長，同比總計 1073 萬美元。分析師對該股票的評級不一，整體評級為 “適度買入”，平均目標價為 76.50 美元。內部人士最近出售了股份，顯示出潛在的擔憂</p>

<p>Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities researchers at HC Wainwright lowered their FY2030 earnings estimates for Crinetics Pharmaceuticals in a research note issued to investors on Friday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $2.65 per share for the year, down from their previous forecast of $2.98. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($4.95) per share.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc.（納斯達克代碼：CRNX - 免費報告）- HC Wainwright 的股票研究人員在 5 月 8 日星期五向投資者發佈的研究報告中下調了 Crinetics Pharmaceuticals 的 2030 財年收益預期。HC Wainwright 分析師 D. Tsao 現在預計該公司在這一年將每股盈利 2.65 美元，低於之前預測的 2.98 美元。市場普遍預計 Crinetics Pharmaceuticals 當前全年的每股收益為（4.95 美元）。</p>
</div><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million during the quarter, compared to the consensus estimate of $8.51 million. During the same quarter last year, the firm earned ($1.04) EPS. The business's revenue for the quarter was up 2873.4% on a year-over-year basis.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals（納斯達克代碼：CRNX - 獲取免費報告）最近在 5 月 7 日星期四發佈了季度財報。該公司報告季度每股收益為（1.23 美元），低於市場普遍預期的（1.22 美元）0.01 美元。Crinetics Pharmaceuticals 的股本回報率為負 43.96%，淨利潤率為負 2,747.18%。該公司在本季度的收入為 1,073 萬美元，而市場普遍預期為 851 萬美元。去年同期，該公司每股收益為（1.04 美元）。該公司的季度收入同比增長 2873.4%。</p>
</div><p>Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Crinetics Pharmaceuticals from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday. Lifesci Capital upgraded Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Friday, February 13th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Finally, Citizens Jmp reduced their target price on shares of Crinetics Pharmaceuticals from $97.00 to $95.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $76.50.</p>
<div class="lb-trans"><p>其他幾位股票分析師也對該公司發佈了報告。Wall Street Zen 在週六的研究報告中將 Crinetics Pharmaceuticals 的評級從 “賣出” 下調至 “強烈賣出”。Lifesci Capital 在 2 月 13 日星期五的研究報告中將 Crinetics Pharmaceuticals 的評級上調至 “強烈買入”。Weiss Ratings 在 4 月 20 日星期一的報告中重新發布了對 Crinetics Pharmaceuticals 股票的 “賣出（d-）” 評級。高盛集團在 1 月 12 日星期一的研究報告中將 Crinetics Pharmaceuticals 的股票評級從 “中性” 上調至 “買入”，並設定了 67.00 美元的目標價。最後，Citizens Jmp 在週五的研究報告中將 Crinetics Pharmaceuticals 的目標價從 97.00 美元下調至 95.00 美元，並對該股票設定了 “市場表現優於大盤” 的評級。一位研究分析師給予該股票 “強烈買入” 評級，八位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Crinetics Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 76.50 美元。</p>
</div><p><strong>Get Our Latest Analysis on CRNX</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 CRNX 的最新分析</strong></p>
</div><h2>Crinetics Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 股票表現</h2>
</div><p>Shares of CRNX opened at $37.48 on Monday. The business's fifty day moving average price is $38.41 and its two-hundred day moving average price is $43.89. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -7.31 and a beta of 0.28. Crinetics Pharmaceuticals has a 52 week low of $25.83 and a 52 week high of $57.99.</p>
<div class="lb-trans"><p>CRNX 的股票在週一開盤價為 37.48 美元。該公司的 50 日移動平均價格為 38.41 美元，200 日移動平均價格為 43.89 美元。該公司的市值為 39.5 億美元，市盈率為 -7.31，貝塔值為 0.28。Crinetics Pharmaceuticals 的 52 周低點為 25.83 美元，52 周高點為 57.99 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 21,981 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief executive officer owned 404,778 shares of the company's stock, valued at approximately $15,126,553.86. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeff E. Knight sold 85,163 shares of the firm's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total value of $3,415,036.30. Following the transaction, the insider owned 105,289 shares in the company, valued at approximately $4,222,088.90. This trade represents a 44.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 142,380 shares of company stock worth $5,569,475 over the last three months. Insiders own 3.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Crinetics Pharmaceuticals 的新聞中，首席執行官 Richard Scott Struthers 於 3 月 16 日星期一出售了 21,981 股該股票。該股票以平均價格 37.37 美元出售，總價值為 821,429.97 美元。交易後，首席執行官持有該公司 404,778 股股票，價值約為 15,126,553.86 美元。這代表了他們持股比例的 5.15% 的減少。該交易在向 SEC 提交的文件中披露，相關信息可通過 SEC 網站訪問。此外，內部人士 Jeff E. Knight 於 4 月 8 日星期三出售了 85,163 股該公司的股票。該股票以平均價格 40.10 美元出售，總價值為 3,415,036.30 美元。交易後，內部人士持有該公司 105,289 股股票，價值約為 4,222,088.90 美元。這筆交易代表了他們持股比例的 44.72% 的減少。該銷售的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去三個月內出售了價值 5,569,475 美元的 142,380 股公司股票。內部人士持有該公司 3.80% 的股票。</p>
</div><h2>Institutional Trading of Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Crinetics Pharmaceuticals by 55.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 852,258 shares of the company's stock valued at $30,935,000 after acquiring an additional 303,281 shares during the period. SEB Asset Management AB acquired a new position in Crinetics Pharmaceuticals during the first quarter valued at approximately $7,769,000. Principal Financial Group Inc. increased its stake in Crinetics Pharmaceuticals by 32.3% in the first quarter. Principal Financial Group Inc. now owns 7,066 shares of the company's stock valued at $257,000 after purchasing an additional 1,725 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in Crinetics Pharmaceuticals by 4.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,477 shares of the company's stock valued at $1,034,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in Crinetics Pharmaceuticals in the first quarter worth $126,000. 98.51% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近修改了對該股票的持有。Dimensional Fund Advisors LP 在第一季度將其在 Crinetics Pharmaceuticals 的持倉增加了 55.2%。Dimensional Fund Advisors LP 現在擁有 852,258 股該公司的股票，價值 30,935,000 美元，在此期間又收購了 303,281 股。SEB Asset Management AB 在第一季度收購了 Crinetics Pharmaceuticals 的新頭寸，價值約為 7,769,000 美元。Principal Financial Group Inc. 在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 32.3%。Principal Financial Group Inc. 現在擁有 7,066 股該公司的股票，價值 257,000 美元，在上個季度又購買了 1,725 股。肯塔基州教師退休系統在第一季度將其在 Crinetics Pharmaceuticals 的持股增加了 4.0%。肯塔基州教師退休系統現在擁有 28,477 股該公司的股票，價值 1,034,000 美元，在上個季度又購買了 1,100 股。最後，Fifth Third Bancorp 在第一季度收購了 Crinetics Pharmaceuticals 的新股份，價值 126,000 美元。98.51% 的股票由機構投資者持有。</p>
</div><h2>About Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Crinetics Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化用於治療罕見內分泌疾病的新型治療藥物。該公司的專有平台利用對激素受體信號傳導的洞察，設計小分子候選藥物，以解決由激素活動失調引起的疾病。Crinetics 的研究工作集中在針對生長抑素、抗利尿激素和其他 GPCR 介導的通路，旨在改善患者的便利性和依從性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 paltusotine（前稱 CRN04777）是一種選擇性非肽類生長抑素受體 2 型激動劑，正在評估用於治療肢端肥大症和類癌綜合症腹瀉。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Crinetics Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關投資機會</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後獲得提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Crinetics Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Crinetics Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Crinetics Pharmaceuticals 並不在名單上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Crinetics Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 Crinetics Pharmaceuticals 2030 財年的收益預估為負